Hikma Outlines Injectables Growth Amid Slow Start For Generics

Generics Revenues Expected To Be Weighted Towards Second Half Of 2022

 
• By David Wallace
  
Growth man drawing graph pen
Hikma has set out its injectables growth expectations after acquiring Custopharm • Source: Christian Horz / Alamy Stock Photo
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business